King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells

King Faisal Specialist Hospital and Research Centre Celebrates the Success of Treating 100 Patients with Lymphocytic Leukemia Using CAR T-Cells

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — In a new step that offers cancer patients a glimmer of hope and a lifeline, the King Faisal Specialist Hospital and Research Centre (KFSH&RC) celebrated its success in treating the 100th patient with lymphoid leukemia using Chimeric Antigen Receptor T-cell (CAR T-cell) therapy. This aligns with KFSH&RC’s vision to be the optimal choice for specialized healthcare.

CAR T-cell therapy is an innovative treatment that enhances the ability of T-cells to recognize and destroy cancer cells after genetic modification in the laboratory to improve their targeting ability. This approach overcomes the challenge of distinguishing between cancer and normal cells, offering a promising method for treating lymphoid leukemia.

KFSH&RC emphasized that this innovative technology provides hope for patients with resistant leukemia and lymphoid tumors, especially those not effectively treatable with traditional methods.

As a strategic healthcare partner, KFSH&RC is sharing information about CAR T-cell therapy, its positive impact on healthcare improvement, and various healthcare solutions and innovations during the Global Health Exhibition taking place in Riyadh from October 29th to 31st.

KFSH&RC Hospital explained that this advanced therapy consists of four stages: extracting blood from the patient to obtain specific cells, then genetically modifying them in the lab for 3-4 weeks.

Shortly before CAR T-cell therapy, the patient receives a low dose of chemotherapy to enhance its effectiveness and the body’s ability to fight cancer. Afterward, CAR T-cells are infused into the patient’s arm, which is closely monitored for four weeks to ensure the body’s adaptation.

The application of this advanced treatment in the Kingdom represents a qualitative addition to specialized medical care, reducing the financial, social, and health burdens of sending such cases abroad, aligning with Saudi Vision 2030 and its healthcare objectives.

King Faisal Specialist Hospital and Research Centre is globally recognized for offering this advanced form of treatment, thanks to its comprehensive therapeutic program featuring highly skilled medical, nursing, pharmaceutical, laboratory, and social specialists supported by an integrated infrastructure.

KFSH&RC is a global leader in specialized healthcare, innovation, advanced research, and medical education. It aims to develop medical technologies and elevate the standard of healthcare worldwide through partnerships with leading local, regional, and international institutions in clinical, research, and educational fields.

Contact information:
kfshrc@mcsaatchi.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9693817f-f8f6-4535-b14c-41f6801f16f7

GlobeNewswire Distribution ID 8968450

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom_01

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — For the past four decades, the Cyclotron and Radiopharmaceuticals Department at King Faisal Specialist Hospital and Research Centre (KFSH&RC) has been addressing the needs of local and regional medical centers for radiopharmaceuticals used in diagnosing and treating various specialized diseases.

Since its establishment, the department has produced over 25 types of radiopharmaceuticals with a production capacity exceeding 600,000 radiopharmaceutical preparations. The department continues to provide its products to over 50 specialized Saudi medical centers, aiming to achieve self-sufficiency in the field of radiopharmaceuticals in the Kingdom of Saudi Arabia.

King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom_02

During the Global Health Exhibition that commenced yesterday in the capital city of Riyadh, where KFSH&RC participates as a strategic health partner, the hospital highlights the department’s pioneering role in nuclear medicine. This includes enhancing the capabilities of healthcare providers in both research and education, as well as ensuring the quality in the production and distribution of radiopharmaceuticals to hospitals across the Kingdom and beyond.

The Cyclotron and Radiopharmaceuticals Department aspires to become a diagnostic and molecular imaging center and the first facility for Technetium-99m (Tc-99m) generators in the Kingdom. It conducts research to develop high-quality radiopharmaceuticals for KFSH&RC and other hospitals throughout the Kingdom to meet all healthcare needs of patients. The department adheres to high-quality standards for automated quality control and assurance while striving to advance cyclotron technology, precise radiopharmaceutical manufacturing, and the development of radiopharmaceuticals used in positron emission tomography/computed tomography (PET/CT).

The department significantly emphasizes quality, with an integrated product quality control and management unit, manufacturing materials following Good Manufacturing Practices (GMP), the Saudi Food and Drug Authority (SFDA) standards, and ISO 9001 international quality management system standards. All operational processes are subjected to rigorous monitoring for the periodic evaluation of materials, ensuring their continuous suitability. This approach has led to a remarkable customer satisfaction rate exceeding 95%.

KFSH&RC is globally recognized for providing specialized healthcare and is a leader in innovation, advanced medical research, and medical education. The institution actively seeks to develop medical technologies and enhance the standard of healthcare worldwide, partnering with leading local, regional, and international organizations to deliver world-class services in clinical, research, and educational domains.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/ad78d2ea-0d15-45ae-a3bd-cd25f7bf7ab9

https://www.globenewswire.com/NewsRoom/AttachmentNg/1d1f90e9-3a44-43cf-8812-af6760e2d0b2

GlobeNewswire Distribution ID 8968426

Zoom AI Companion hits one million meeting summaries milestone

AI Companion will expand support for 32 new languages, new capabilities for Zoom Events, in-meeting questions, and meeting coaching

SAN JOSE, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) — Today Zoom Video Communications, Inc. (NASDAQ: ZM) announced that Zoom AI Companion, the company’s generative AI assistant, has reached a milestone less than two months after its launch, with more than 125,000 accounts using AI Companion, generating more than one million meeting summaries. Zoom also announced new capabilities, additional language support, and further enhancements to existing capabilities for AI Companion.

“Providing the best value to our customers across our platform is core to our mission, which is why we made AI Companion available at no additional cost,1 and we continue to introduce new AI capabilities at Zoom speed, so more of our customers can get the most out of Zoom’s AI innovations,” said Smita Hashim, chief product officer at Zoom. “Our unique federated approach allows us to dynamically utilize different models, helping to reduce AI overhead costs and provide broad access to generative AI.”

New Zoom AI Companion capabilities
Beginning today, AI Companion users will be able to use the in-meeting questions capability in new languages, as well as receive short meeting summary overviews at the beginning of full meeting summaries.

  • Users can now use AI Companion’s in-meeting questions capability in seven new languages (preview).
  • Based on feedback from users, the meeting summaries capability now includes an overview at the top of the summary in emailed summaries, providing users with a shorter version of the meeting summary in addition to the full meeting summary. Meeting summary overviews will be available in summaries delivered via continuous meeting chat in November.

AI Companion capabilities available in November

Zoom will continue to improve AI Companion, with the following new capabilities planned to be available in November:

  • Both AI Companion meeting summary and in-meeting questions capabilities will support a total of 32 new languages, in preview.
  • AI Companion will provide users with meeting coach capabilities, beginning with speech analytics in Smart Recordings. Speech analytics will include the meeting host’s talk-listen ratio, talk speed, and speech fillers so that hosts can glean valuable insights into how they engage with meeting participants during Zoom Meetings.
  • AI Companion will be available in Zoom Events, with chat compose capabilities for lobby chats and assistance with composing emails for registration, marketing, and ticketing communications.
  • Zoom will introduce an optional control for customers to specify that AI Companion capabilities for their organization only use the Zoom large language model.

What Zoom customers are saying about AI Companion

“AI Companion’s meeting summaries and smart recordings are the first technological innovations in the last decade that bring us tangible time-saving, efficient benefits. People can prioritize specific meetings and collaborations while remaining confident they aren’t missing out on competing activities.” – Chris Blackstone, director, Digital Workplace and End User Computing, Convera

“Zoom’s AI Companion meeting summary tool is helping us become better communicators. Guided by its impressively accurate output, our teams are more consistently adhering to best practices in meetings such as stating the objective upfront and clearly outlining and assigning action items. Plus, we were able to save money by offboarding a vendor and save time by not having to produce meeting notes ourselves.” – Lucas Oliveira, COO, Bizzycar, Inc.

“Meeting summaries has saved our team a ton of time. We feel that everyone is in the loop without necessarily having to attend every meeting, which results in better collaboration.” – Karl Morsgofian, CIO, Gainsight

“Zoom’s AI Companion exemplifies our vision for enhanced collaboration and innovation. With automated, detailed meeting summaries, it streamlines information sharing and boosts productivity. This inclusion in our Zoom plan not only improves efficiency but also yields significant cost savings, reflecting our commitment to a smarter, more connected future.” – John Georgatos, CIO, Mike Morse Law Firm

AI Companion is available for eligible paid Zoom user accounts at no additional cost.1 For more information about Zoom AI Companion, visit the Zoom website.

About Zoom
Zoom is an all-in-one intelligent collaboration platform that makes connecting easier, more immersive, and more dynamic for businesses and individuals. Zoom technology puts people at the center, enabling meaningful connections, facilitating modern collaboration, and driving human innovation through solutions like team chat, phone, meetings, omnichannel cloud contact center, smart recordings, whiteboard, and more, in one offering. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more info at zoom.com.

Forward-Looking Statements

This press release contains express and implied “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected benefits and potential of Zoom’s generative AI assistant. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” “target,” “explore,” “continue,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including those described under the caption “Risk Factors” and elsewhere in our most recent filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2023. Forward-looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

Zoom Public Relations
Lacretia Taylor
press@zoom.us

1 Note: Included at no additional cost with the paid services assigned to Zoom accounts. AI Companion may not be available for all regions and industry verticals.

GlobeNewswire Distribution ID 8968304

Leading Japanese Telecommunications Carrier SoftBank Corp. Deploys Synchronoss Personal Cloud

Roll Out of Anshin Data Box Powered by Synchronoss Personal Cloud Integrates Artificial Intelligence Functionality and Enables Customers to Optimize, Organize, and Safeguard Photos, Videos, and Other Digital Content

BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging, and digital products and platforms, today announced that SoftBank Corp. (“SoftBank”), one of Japan’s largest telecommunication carriers, has deployed Synchronoss Personal Cloud to power its Anshin Data Box service.

Anshin Data Box allows customers to backup and restore photos, videos, and files stored on mobile phones and other devices. Additionally, the platform’s artificial intelligence features provide the capability to optimize low resolution photos and create new types of content through a series of effects and stylizers.

Available in November across multiple distribution channels, SoftBank’s Anshin Data Box will include 500 gigabytes of storage per month. Additionally, the personal cloud service will be integrated into new devices, allowing customers to easily activate it during the onboarding process. SoftBank will also deliver Anshin Data Box through its retail stores and digital buy flow.

“We continue to empower telecom operators and mobile service providers with strategic tools to improve customer value,” said Jeff Miller, President and CEO of Synchronoss. “This new Cloud launch with SoftBank further extends our long-standing relationship with them and our presence in Japan. It also reinforces our cloud-first strategy, which represents new growth opportunities for the Synchronoss Personal Cloud platform.”

About Synchronoss
Synchronoss Technologies (Nasdaq: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs, and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services, and content they love. Learn more at www.synchronoss.com.

Media Relations Contact:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Investor Relations Contact:
Matt Glover and Tom Colton
Gateway Group, Inc.
SNCR@gateway-grp.com

GlobeNewswire Distribution ID 8968023

King Faisal Specialist Hospital and Research Centre Announces Rapid Whole Genome Sequencing Service

KFSH&RC Rapid Whole Genome Sequencing _ 01

KFSH&RC Rapid Whole Genome Sequencing _ 01

RIYADH, Saudi Arabia, Oct. 30, 2023 (GLOBE NEWSWIRE) — In a groundbreaking development for the Middle East, King Faisal Specialist Hospital and Research Centre (KFSH&RC) has introduced a service called Rapid Whole-Genome Sequencing (rWGS) as part of its healthcare solutions. This service is designed to help doctors diagnose rare and genetic disorders, particularly in critically ill newborns, who require fast and precise identification of their conditions.

The Rapid Whole Genome Sequencing service is invaluable for newborns with rare diseases, as it helps them avoid the often lengthy process of tests and treatments that can stretch for months or even years without a precise diagnosis. This increases the chances of survival and reduces the overall healthcare cost by minimizing hospital admissions, unnecessary tests, and medical care.

KFSH&RC Rapid Whole Genome Sequencing _ 02

KFSH&RC Rapid Whole Genome Sequencing _ 02

Remarkably, the hospital has reduced the time required for this genetic testing from the typical two-month duration to less than 35 hours. Response time is paramount when planning healthcare for critically ill newborns, and swift delivery of test results ensures a prompt and tailored medical response, preventing delays that could otherwise lead to worsening the patient’s condition or even death.

As part of its participation in the Global Health Summit, where KFSH&RC plays a vital role as a strategic healthcare partner, the hospital shares details about the Rapid Whole Genome Sequencing service at its exhibition booth. The hospital’s cutting-edge capabilities include analyzing up to 99% of DNA sequences from patient blood samples, along with several innovative healthcare solutions.

The comprehensive genetic composition examination involves a streamlined four-step process. First, the DNA is broken down into manageable segments. Then, it is encoded with a barcode-like symbol for easy identification, similar to tracking products in a store. The examination itself is conducted using specialized equipment. Finally, advanced computer systems and software compare these sequences, identifying differences in DNA sequences and pinpointing the genetic mutations responsible for diseases.

KFSH&RC provides the highest level of healthcare and offers the best possible patient experience within an integrated educational and research environment. It collaborates and shares expertise with leading local, regional, and international institutions to provide a globally competitive service in clinical, research, and educational fields.

Globally renowned for its specialized healthcare, KFSH&RC is a pioneer in medical innovation and a hub for advanced medical research and education. It is committed to advancing medical technologies and raising the standard of healthcare worldwide through partnerships with top local, regional, and international institutions in clinical, research, and educational sectors.

Contact information:
kfshrc@mcsaatchi.com

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/59bc8aa4-5f6d-432a-b4e9-c26544e9aa6d

https://www.globenewswire.com/NewsRoom/AttachmentNg/76f80d26-8e56-42df-b95a-c8cdab80e449

GlobeNewswire Distribution ID 8968201